T
Tito R. Mendoza
Researcher at University of Texas MD Anderson Cancer Center
Publications - 6
Citations - 52
Tito R. Mendoza is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: MD Anderson Symptom Inventory - Brain Tumor & Cronbach's alpha. The author has an hindex of 4, co-authored 6 publications receiving 26 citations. Previous affiliations of Tito R. Mendoza include Henry Ford Hospital.
Papers
More filters
Journal ArticleDOI
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Mark R. Gilbert,Ying Yuan,Jimin Wu,Tito R. Mendoza,Tito R. Mendoza,Elizabeth Vera,Antonio Omuro,Frank S. Lieberman,H. Ian Robins,Elizabeth R. Gerstner,Jing Wu,Patrick Y. Wen,Tom Mikkelsen,Kenneth Aldape,Terri S. Armstrong +14 more
TL;DR: This treatment, with demonstrated clinical activity with objective responses and prolonged disease control associated with disease-related symptom improvements is an option as a salvage regimen for adult patients with recurrent ependymoma.
Journal ArticleDOI
Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Loretta A. Williams,Meagan Whisenant,Tito R. Mendoza,Shireen Haq,Karen Keating,Brian Cuffel,Charles S. Cleeland +6 more
TL;DR: The MDASI-MPM has established content validity and, with the addition of one symptom item, is ready for psychometric testing as fit-for-purpose for a clinical trial of an investigational agent.
Journal ArticleDOI
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.
Tito R. Mendoza,Ajay Sheshadri,Mehmet Altan,Kenneth R. Hess,Goldy C. George,Bettzy Stephen,Lilibeth Castillo,Enedelia Rodriguez,Jing Gong,Christine B. Peterson,Jordi Rodon Ahnert,Siqing Fu,Sarina Anne Piha-Paul,Shubham Pant,Ecaterina Ileana Dumbrava,Timonthy A Yap,Filip Janku,Apostolia Maria Tsimberidou,Vivek Subbiah,Daniel D. Karp,Abdulrazzak Zarifa,Lacey McQuinn,Charles S. Cleeland,David S. Hong,Aung Naing +24 more
TL;DR: The psychometric properties of the Immunotherapy for Early-Phase Trials module of the MD Anderson Symptom Inventory (MDASI-Immunotherapy EPT) in patients receiving various immunotherapies in early phase trials at a major cancer center are presented.
Journal ArticleDOI
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
Tito R. Mendoza,Loretta A. Williams,Karen Keating,Jonathan Siegel,Cem Elbi,Anna K. Nowak,Raffit Hassan,Brian Cuffel,Charles S. Cleeland +8 more
TL;DR: The MDASI-MPM was found to be a valid, reliable, and responsive (sensitive) instrument for assessing the severity of symptoms of patients with MPM and their interference in patients’ daily functioning.
Journal ArticleDOI
The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment.
Tito R. Mendoza,Loretta A. Williams,Qiuling Shi,Xin Shelley Wang,Oluwatosin Bamidele,Jeanie F. Woodruff,Charles S. Cleeland +6 more
TL;DR: A revised version of the Treatment-induced Neuropathy Assessment Scale (TNAS) is reported, incorporating extensive patient input, in accordance with FDA guidance on the development of patient-reported outcomes measures.